Avantor
Avantor supplies lab materials, equipment and services to biopharma, healthcare and industrial customers worldwide.
The call
Avantor's installed base and validated materials keep customers from leaving fast, but shrinking organic sales and thinner margins show that base is not growing.
Avantor sells chemicals and equipment to pharmaceutical and biotech labs. It is hard to replace because its products are already baked into customers' FDA-approved manufacturing processes, but that lock-in only protects existing deals, not new ones. Thermo Fisher Scientific, a much larger competitor, is steadily taking market share, and Avantor's own sales have shrunk for two straight years while profits have dropped. The company just replaced its CEO, CFO, and board chair within one year, and it faces a fraud investigation, both of which make it unclear whether new leadership can actually turn things around. The one thing that could change the picture is whether the next two or three quarters show that the company's turnaround plan finally stops the customer losses.
Why
01
AI pressure: AI-driven procurement platforms (e.g. Amazon Business, Jaggaer) automating lab reordering. AI procurement tools could let labs bypass distributor sales reps and price lists, squeezing Avantor's order-taking role. Could AI do the core job? Unlikely.
02
Bigger players: Thermo Fisher Scientific. Thermo Fisher sells overlapping lab consumables, equipment and services at larger scale, competing directly for the same customers. Could a giant copy it? Yes, easily.
03
What protects it. Its materials are validated inside customers' FDA-approved manufacturing lines, so swapping suppliers means re-validating production, which labs avoid.
What would change this call
Avantor's Q2 2026 earnings (July 29, 2026) show organic revenue still negative. Turnaround has not stopped share loss to bigger rivals.
Avantor names a permanent CFO in 2026. Leadership instability easing, capital allocation may stabilize.
Bronstein Gewirtz securities investigation results in a filed lawsuit. Legal risk escalates beyond current investigation stage.
Avantor names a permanent CFO in 2026. Leadership instability easing, capital allocation may stabilize.
Bronstein Gewirtz securities investigation results in a filed lawsuit. Legal risk escalates beyond current investigation stage.
Key numbers
- FY2025 net sales $6,552.2M
- Q1 2026 organic sales down 4% YoY
- FY2026 guided EBITDA margin 14.8-15.3%
Named risks
- Active securities-fraud investigation by Bronstein Gewirtz covering pre-March 2024 shareholders, ongoing through July 2026.
- Two consecutive years of organic revenue decline with FY2026 guidance still negative.
- Leadership churn: new CEO, CFO vacancy since March 2026, new CTO and board chair within 12 months.
- Adjusted EBITDA margin compression from 17.7% to 13.9% quarterly, pressuring profitability.
- Middle East conflict related inflation adding estimated $10-20M FY2026 operating income headwind.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Thermo Fisher Scientific | losing to | Avantor organic revenue guidance still negative (-2.5% to -0.5%) as of 2026-04-29 while larger rival faces no structural block |
| Merck KGaA (MilliporeSigma) | contesting | Competing life-science reagents and materials supplier, cited as R&D-driven portfolio leader, mid-2026 |
| Sartorius Stedim Biotech | contesting | Key bioprocessing and single-use technology competitor per industry analysis, June 2026 |
| Danaher (Cytiva) | contesting | Bioprocessing competitor; Avantor hired ex-Danaher/Cytiva exec Ludovic Brellier as CTO, May 2026 |
| Corning Life Sciences | contesting | Cited alongside Thermo Fisher and Sartorius as bioprocessing and lab-materials rival, June 2026 |
Questions people ask
- Is Avantor profitable in 2026?
- Mixed. Avantor posted a GAAP net loss of $530.2M for full-year 2025 (as of 2025-12-31), but returned to profit with $43M net income in Q1 2026 (quarter ended 2026-03-31). Adjusted EBITDA margin fell to 13.9% in Q1 2026 from 17.0% a year earlier, per its April 29, 2026 earnings release.
- Who owns Avantor?
- Avantor is a public company (NYSE: AVTR) that IPO'd on May 17, 2019 at $14/share. Originally built by private-equity firm New Mountain Capital after its 2010 Mallinckrodt Baker deal, ownership has since shifted overwhelmingly to institutional investors following the IPO and subsequent secondary sell-downs.
- Is Avantor losing market share to Thermo Fisher Scientific?
- Signs point that way. Avantor's organic revenue has declined for two straight years, averaging about -2.1% annually through Q1 2026, and FY2026 guidance (issued April 29, 2026) still projects -2.5% to -0.5% organic growth, while larger rival Thermo Fisher faces no structural block to taking share.
- Could AI replace Avantor's business?
- Unlikely to replace its core function. Avantor's value sits in physical distribution scale, ISO-certified quality processes, and bioprocess materials validated inside customers' FDA-regulated manufacturing lines, largely AI-resistant moats. Avantor itself uses AI internally, including a Decision Intelligence platform with Aera Technology (62 enhancements queued as of Feb 2026).
- Is it safe to take a job at Avantor right now?
- The paycheck looks stable given ~$6.55B in FY2025 revenue and positive free cash flow ($496M in FY2025), but leadership has churned heavily: new CEO (Aug 2025), CFO resignation (March 26, 2026), new Chief Transformation Officer (May 1, 2026), and a new board chair (Jan 2026), all mid-turnaround.
- What is Avantor's biggest competitor?
- Thermo Fisher Scientific is Avantor's largest and most direct competitor in lab distribution, described by industry sources as the market leader with Avantor/VWR as the clear number-two player in the US as of mid-2026. MilliporeSigma, Sartorius, and Danaher/Cytiva compete in bioprocessing.
Timeline
- 2026-07-21Bronstein Gewirtz Grossman announces continued securities fraud investigation into Avantor
- 2026-05-19Gerard Porreca appointed EVP for Quality and Regulatory
- 2026-05-01Ludovic Brellier becomes EVP of Bioscience and Medtech Products and Chief Transformation Officer
- 2026-04-29Q1 2026 results: net sales $1,581M, adjusted EBITDA margin 13.9%, stock surges on beat
- 2026-03-26CFO R. Brent Jones resigns; Steve Eck named interim CFO
- 2026-02-11FY2025 results reported: net sales $6,552.2M, GAAP net loss $530.2M
- 2026-01-01Gregory Summe becomes non-executive Chairman of the Board
- 2025-08-18Emmanuel Ligner becomes President and CEO
- 2019-05-17Avantor IPOs on NYSE at $14 per share, ~$7.6B market cap
- 2017-01-01Avantor acquires VWR International for approximately $6.4 to 6.5B
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Avantor Reports Fourth Quarter and Full Year 2025 Results (2026-02-11)
- Avantor Reports First Quarter 2026 Results (2026-04-29)
- AVTR Q1 CY2026 Sales Beat Estimates (2026-04-29)
- Avantor Q1 2026 slides show turnaround progress (2026-04-29)
- Avantor Q1 2026 Earnings Transcript (2026-04-29)
- Avantor (AVTR) Number of Employees 2018-2025 (2026-07-01)
- Avantor Number of Employees 2026 (2026-06-29)
- Who Owns Avantor Company? (2026-04-03)
- VWR Company Analysis & Supplier Recommendations (2026-07-09)
- Clarkston Capital Partners LLC Lowers Stock Position (2026-07-24)
- Avantor Announces CFO Transition (2026-04-01)
- Avantor Appoints Ludovic Brellier (2026-06-01)